Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) major shareholder Financial Lp Hrt sold 3,183 shares of Clearmind Medicine stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $3.32, for a total transaction of $10,567.56. Following the sale, the insider owned 103,492 shares of the company’s stock, valued at approximately $343,593.44. The trade was a 2.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Friday, June 12th, Financial Lp Hrt sold 2,102 shares of Clearmind Medicine stock. The shares were sold at an average price of $3.36, for a total transaction of $7,062.72.
- On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The shares were sold at an average price of $0.12, for a total transaction of $27,022.92.
- On Wednesday, June 10th, Financial Lp Hrt acquired 2,159,052 shares of Clearmind Medicine stock. The shares were acquired at an average price of $0.15 per share, with a total value of $323,857.80.
Clearmind Medicine Stock Performance
Shares of NASDAQ CMND opened at $3.14 on Thursday. Clearmind Medicine Inc. has a 12 month low of $2.10 and a 12 month high of $524.00. The company has a 50 day simple moving average of $5.75 and a two-hundred day simple moving average of $15.22. The stock has a market cap of $3.20 million, a price-to-earnings ratio of -0.02 and a beta of 0.64.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen raised shares of Clearmind Medicine to a “sell” rating in a report on Saturday, May 23rd.
View Our Latest Report on Clearmind Medicine
Clearmind Medicine Company Profile
Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.
Clearmind’s pipeline includes multiple preclinical and early clinical candidates.
Further Reading
- Five stocks we like better than Clearmind Medicine
- 2 Quantum Stocks Are Drawing Capital as AI Infrastructure Hits a Wall
- After an Initial Panic, Wall Street’s Leaning Into Apple’s New Siri AI
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
